Mechanism of action
• antiplatelet agent that inhibits the formation of thromboxane A2. This inhibition reduces reocclusion recurrent coronary events after fibrinolytic therapy, reducing mortality
• Administer as soon as possible to all patients with suspected AMI or ACS, especially candidates
• 160 to 325 mg.
• Relatively contraindicated in patients with active peptic ulcer disease and a history of asthma (more…)
Posts Tagged ‘aspirin’